Finance

Lists
BIOCON:NSE
Biocon Ltd
349,20 ₹
-0,80%
(-2,80) 1D
16 հոկ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
352,60 ₹
High
353,00 ₹
Low
348,00 ₹
Mkt. cap
568,79 մլրդ
Avg. vol.
2,97 մլն
Volume
1,88 մլն
Dividend
0,14%
Quarterly dividend
0,12 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
103,38
52-wk high
447,15 ₹
52-wk low
337,70 ₹
EPS
3,38 ₹
Shares outstanding
600,00 մլն
No. of employees
16 հզր
Open
352,60 ₹
High
353,00 ₹
Low
348,00 ₹
Mkt. cap
568,79 մլրդ
Avg. vol.
2,97 մլն
Volume
1,88 մլն
Dividend
0,14%
Quarterly dividend
0,12 ₹
Ex-dividend date
03 հլս, 2026 թ.
P/E ratio
103,38
52-wk high
447,15 ₹
52-wk low
337,70 ₹
EPS
3,38 ₹
Shares outstanding
600,00 մլն
No. of employees
16 հզր
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16,4 հզր
Founded29 նոյ, 1978 թ.
HeadquartersԲանգալոր, Կառնատակա, Հնդկաստան
Sector-
Websitebiocon.com
Last report
06 օգս, 2026 թ.
Fiscal period
Q1 2027
0,95 ₹ / 1,09 ₹
-12,68%miss
Revenue / Est. (INR)
43,36 մլրդ / 44,74 մլրդ
-3,08%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
42,96 մլրդ
41,73 մլրդ
45,17 մլրդ
43,36 մլրդ
Cost of goods sold
17,72 մլրդ
13,39 մլրդ
23,69 մլրդ
14,68 մլրդ
Cost of revenue
17,72 մլրդ
13,39 մլրդ
23,69 մլրդ
14,68 մլրդ
Research and development expenses
-132,00 մլն
-531,00 մլն
-128,00 մլն
-16,00 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,59 մլրդ
8,75 մլրդ
13,28 մլրդ
9,16 մլրդ
Operating expense
21,18 մլրդ
25,16 մլրդ
14,45 մլրդ
25,69 մլրդ
Total operating expenses
38,90 մլրդ
38,55 մլրդ
38,14 մլրդ
40,36 մլրդ
Operating income
4,05 մլրդ
3,18 մլրդ
7,03 մլրդ
3,00 մլրդ
Other non operating income
94,00 մլն
1,17 մլրդ
-2,52 մլրդ
545,00 մլն
EBT including unusual items
1,71 մլրդ
-678,00 մլն
2,48 մլրդ
1,28 մլրդ
EBT excluding unusual items
1,23 մլրդ
2,26 մլրդ
1,80 մլրդ
1,41 մլրդ
Income tax expense
385,00 մլն
-160,00 մլն
489,00 մլն
-92,00 մլն
Effective tax rate
22,48%
23,60%
19,76%
-7,21%
Other operating expenses
6,72 մլրդ
11,78 մլրդ
-4,12 մլրդ
11,07 մլրդ
Net income
845,00 մլն
1,44 մլրդ
1,26 մլրդ
1,41 մլրդ
Net profit margin
1,97%
3,45%
2,79%
3,25%
Earnings per share
0,72
2,74
1,27
0,95
Interest and investment income
235,00 մլն
-
1,15 մլրդ
-
Interest expense
-2,72 մլրդ
-2,10 մլրդ
-2,06 մլրդ
-2,13 մլրդ
Net interest expenses
-2,49 մլրդ
-2,10 մլրդ
-906,00 մլն
-2,13 մլրդ
Depreciation and amortization charges
4,73 մլրդ
5,15 մլրդ
5,13 մլրդ
5,47 մլրդ
EBITDA
8,69 մլրդ
7,13 մլրդ
11,62 մլրդ
7,59 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps